SCHEMBL8194202

SCHEMBL8194202

NCc1ccc(N2CCOCC2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
MAPT P10636 6/20 0.46
ALDH1A1 P00352 4/20 0.44
HTT P42858 4/20 0.44
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 3/20 0.44
HSD17B10 Q99714 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
AKR1C3 P42330 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CYP1A2 P05177 1/20 0.43
LGMN Q99538 1/20 0.42
ALOX15 P16050 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3650490 0.83 POLB (0.51) POLBMAPTALDH1A1HTTKDM4E
SCHEMBL807518 0.83 POLB (0.51) POLBMAPTALDH1A1HTTKDM4E
SCHEMBL15530460 0.83 PKM (0.57) ALDH1A1AKT1PIK3CAMTOR
SCHEMBL10233103 0.83 MAPT (0.49) POLBMAPTALDH1A1HTTKDM4E
SCHEMBL18929856 0.81 POLB (0.49) POLBMAPTALDH1A1HTTKDM4E
SCHEMBL18115210 0.81 POLB (0.49) POLBMAPTALDH1A1HTTKDM4E
SCHEMBL28943557 0.80 MAPT (0.49) MAPTALDH1A1HTTKDM4EMEN1
SCHEMBL29493254 0.80 MAPT (0.49) MAPTALDH1A1HTTKDM4EMEN1
SCHEMBL16260486 0.80 POLB (0.48) POLBMAPTALDH1A1HTTKDM4E
SCHEMBL20582236 0.78 POLB (0.47) POLBMAPTALDH1A1SMN1; SMN2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298314-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-11-25 US disclosed
US-20100298314-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-11-25 US disclosed
WO-2008082490-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298314-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK2, MAP4K2 POLB 2431/4885MAPT 1863/4885ALDH1A1 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.